QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe Stephenson who wrote (40)	8/23/1996 10:40:00 PM
From: John Metcalf	of 1321

Gadolite is an MRI contrast agent for imaging the GI tract. Being metallic (Gadolinium), it provides intense imaging. A New Drug Application was filed with the FDA in September. They have also filed for approval in U.K. Gadolite is not a PDT agent. The significance of the product to PCYC's PDT program is that profits from Gadolite could fund development of PDT agents. PCYC has a unique family of texaphyrins -- "Texas-sized porphyrins" with some unique therapeutic characteristics. Some examples -- they have a radiation sensitizer that binds to cancerous cells, a PDT agent which can be used in deep tissue and with pigmented cancers, and a program in using PDT in atheromatous plaque (a potential alternative to coronary angioplasty). There was an article on PDT in Business Week on 6/10/96. It gave an overview of the field, and discussed the major companies working on PDT.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next